ClinicalTrials.gg
Active, not recruitingNCT06345482Updated Nov 20, 2025

A Study of MHB039A for Advanced Solid Tumor

A Phase 1/2 interventional study of MHB039A in Advanced Solid Tumor, sponsored by Minghui Pharmaceutical (Hangzhou) Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Minghui Pharmaceutical (Hangzhou) Ltd (part of Minghui Pharmaceutical) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
196
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.

Read the detailed description

This first-in-human, dose escalation and dose expansion study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of MHB039A in patients with advanced solid tumor. The Phase I stage (dose escalation)is to determine the maximum tolerated dose (MTD). The phase II stage (dose expansion)is to determine the recommended Phase 2 dose (RP2D) according to safety and efficacy in specific tumor types.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Minghui Pharmaceutical (Hangzhou) Ltd is the lead sponsor of 20 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented advanced or solid tumor that is /relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
  • Written and signed
  • Aged 18 years or older
  • (ECOG) Performance Score of 0 or 1
  • >=3 months

Exclusion criteria

Exclusion Criteria:

  • Prior active within the previous 5 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, (e.g. basal cell skin cancer, or carcinoma in situ of the cervix or others)
  • Receiving any chemotherapy within 3 weeks prior to the first dose;or other systemic anticancer therapy within 4 weeks prior to the first dose
  • Receiving prior , anti-PD-L1, anti-CTLA(cytotoxic T-lymphocyte-associated protein)-4 or any other immunotherapy or immune-oncology (IO) agent within 28 days of first dose with MHB039A or experienced a toxicity that led to permanent discontinuation of prior immunotherapy
  • Unresolved toxicities from prior anticancer therapy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
196 participants (estimated)

Study arms

  • Experimental
    MHB039A

    MHB039A IV every 2 weeks or every 3 weeks (including 5mg/kg、10mg/kg、20mg/kg and 30mg/kg)

    Drug: MHB039A

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of participants with adverse events (AE)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Until 30 days after last dose of MHB039A

  2. Number of participants with dose-limiting toxicity (DLT)

    DLTs will be assessed during the dose-escalation phase and are defined as toxicities related to MHB039A which meet pre-defined severity criteria and occurs within the first cycle of treatment.

    Time frame: At the end of Cycle 1 (each cycle is 21 days for every three weeks cohort and 28 days for every two weeks cohort)

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of MHB039A

    to analysis the serum concentrations of MHB039A at different timepoints to determine the Cmax of MHB039A

    Time frame: Until 30 days after last dose of MHB039A

  2. The area under the plasma concentration-time curve (AUC) of MHB039A

    to analysis the serum concentrations of MHB039A at different timepoints to determine the AUC of MHB039A

    Time frame: Until 30 days after last dose of MHB039A

  3. To detectable anti-drug antibodies with treated subjects

    The immunogenicity of MHB039A will be assessed by the number of subjects who produce anti-drug antibodies (ADAs).

    Time frame: Until 30 days after last dose of MHB039A

  4. Objective response rate (ORR)

    The ORR is defined as the proportion of subjects with confirmed complete remission (CR) or confirmed partial response (PR), based on RECIST Version 1.1.

    Time frame: Until 30 days after last dose of MHB039A

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Apr 2028, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Apr 3, 2024
StartActual
Apr 16, 2024
Primary completionEst.
Apr 1, 2028
CompletionEst.
Jun 1, 2029
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345482
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Apr 16, 2024
Primary completion
Apr 1, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Nov 20, 2025

Study contacts

Shun Lu, MD
principal investigator · Shanghai Chest Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A

Start the discussion